1. Impact of DNMT3A and IDH1/IDH2 Mutations on Treatment Response with Azacitidine in Myeloid Neoplasms. (April 2017) Authors: Martín, I.; Navarro, B.; Such, E.; Calabuig, M.; Villamón, E.; Sanz, G.; Cervera, J.; Amat, P.; García, F.; Serrano, A.; Mora, E.; Regadera, A.; Pérez, A.; Solano, C.; Tormo, M. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S157 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Response to Azacitidine in a Series of 94 Patients with Chronic Myelomonocytic Leukemia from the Spanish Group of Myelodysplastic Syndromes. (April 2017) Authors: Triguero, A.; Xicoy, B.; Jiménez, M.J.; García, O.; Ramos, F.; Calabuig, M.; Liang, T.H.C.; Arzuaga, J.; Díaz-Beyá, M.; Medina, Á.; Bernal, T.; Brunet, S.; Coll, R.; Collado, R.; Borrás, J.; Talarn, C.; Sanz, G. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Successful treatment of hepatitis C virus infection with sofosbuvir and simeprevir in the early phase of an allogeneic stem cell transplant. Issue 1 (9th February 2016) Authors: Piñana, J.L.; Serra, M.Á.; Hernández‐Boluda, J.C.; Navarro, D.; Calabuig, M.; Solano, C. Journal: Transplant infectious disease Issue: Volume 18:Issue 1(2016) Page Start: 89 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria. (May 2022) Authors: Triguero, A.; Xicoy, B.; Zamora, L.; Jiménez, MJ.; García, O.; Calabuig, M.; Díaz-Beyá, M.; Arzuaga, J.; Ramos, F.; Medina, A.; Bernal, T.; Talarn, C.; Coll, R.; Collado, R.; Chen, T.Hua; Borrás, J.; Brunet, S.; Marchante, I.; Marco, V.; López-Cadenas, F. Journal: Leukemia research Issue: Volume 116(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 211 SPANISH REGISTRY OF ERYTHROPOIETIC STIMULATING AGENTS STUDY: THE LARGEST RETROSPECTIVE STUDY OF ESAS FOR THE TREATMENT OF ANEMIA IN LOWER RISK MDS PATIENTS. Issue 1 (April 2015) Authors: Campelo, M. Diez; Lorenzo, J.I.; Benlloch, L.; Lopez-Pavia, M.; Such, E.; Bernal, T.; Luño, E.; Davila, J.; Ramos, F.; Calabuig, M.; Pomares, H.; Gonzalez, B.; Merchan, B.; Barranco, E.; Tello, R. Sancho; Callejas, M.; Requena, M.J.; Jimenez, M.J.; Pedreño, M.; Vicente, A.I. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S105 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 83 PERCENTAGE OF BLASTS IN CHRONIC MYELOMONOCYTIC LEUKEMIA TYPE-1 HAS NO IMPACT ON OVERALL SURVIVAL IN A SERIES OF PATIENTS FROM THE SPANISH REGISTRY OF MDS. (April 2015) Authors: Xicoy, B.; Such, E.; Garcia, O.; Jimenez, M.J.; Arnan, M.; Bernal, T.; Nomdedeu, B.; Valcárcel, D.; Pedro, C.; Ramos, F.; Amigo, M.L.; Collado, R.; Palomo, L.; Ardanaz, M.T.; Calabuig, M.; Cedena, M.T.; Grau, J.; Sanz, G. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗